Patents by Inventor Magnus Göran GRAM

Magnus Göran GRAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha-1-microglobulin for use in the protection of kidneys in radionuclide therapy
    Patent number: 10960048
    Abstract: This invention relates to ?1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: March 30, 2021
    Assignee: Guard Therapeutics International AB
    Inventors: Bo Åkerström, Sven-Erik Strand, Magnus Göran Gram, Amanda Thuy Tran
  • USE OF ALPHA-1-MICROGLOBULIN FOR PROTECTION OF BONE MARROW CELLS
    Publication number: 20200345810
    Abstract: The present invention relates to alpha-1-microglobulin (A1M) for use in the protection of bone marrow cells in a subject.
    Type: Application
    Filed: November 1, 2018
    Publication date: November 5, 2020
    Inventors: Johan Flygare, Eddie Thordarson, Bo Åkerström, Magnus Göran Gram
  • ALPHA-1-MICROGLOBULIN FOR USE IN THE PROTECTION OF KIDNEYS IN CONNECTION WITH USE OF CONTRAST MEDIA
    Publication number: 20190054142
    Abstract: This invention relates to an alpha-1-microglobulin for use in prevention of contras medium nephropathy.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Applicant: A1M Pharma AB
    Inventors: Martin AUSTIN, Magnus Göran GRAM, Bo ÅKERSTRÖM
  • ALPHA-1-MICROGLOBULIN FOR USE IN THE PROTECTION OF KIDNEYS IN RADIONUCLIDE THERAPY
    Publication number: 20180243369
    Abstract: This invention relates to ?1-microglobulin (A1M) for use in the diagnosis or treatment of malignancies requiring radionuclide diagnostics (RD), radionuclide therapy (RNT) or radioimmunotherapy (RIT), respectively, wherein A1M is used as a co-treatment to RD, RNT or RIT.
    Type: Application
    Filed: February 25, 2016
    Publication date: August 30, 2018
    Applicant: A1M PHARMA AB
    Inventors: Bo Akerstrom, Sven-Erik STRAND, Magnus Göran GRAM, Amanda Thuy TRAN
  • BIOMARKERS FOR PREECLAMPSIA
    Publication number: 20180074070
    Abstract: The present invention relates to the use of hemopexin, free, non-cell bound fetal hemoglobin and alpha-1-micro-globulin as markers for preeclampsia.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 15, 2018
    Applicant: A1M Pharma AB
    Inventors: Stefan HANSSON, Bo AKERSTRÖM, Magnus Göran GRAM